77 completed, 34 unknown, 23 recruiting, 22 terminated. 178 Phase 2, 39 Phase 1, 22 Phase 3.
Follow Lung Injury: new trials by email Literature Review of Lung Injury trials Research Report on Lung Injury
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuous vs Bolus Neuromuscular Blockade Regimens in Moderate to Severe Hypoxemic Respiratory Failure and ARDS (COBRA) Neuromuscular Blocking Agent - Bolus Dosing, Neuromuscular Blocking Agent - Continuous Infusion - ARDS (Acute Respiratory Distress Syndrome) | Phase 2 | Not yet recruiting | University of Calgary | 100 | 2027-01-01 | 2026-05-14 |
| CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO) Caffeine citrate, Saline (NaCl 0,9 %) (placebo) - Meconium Aspiration Syndrome | Phase 2 | Not yet recruiting | University of Alberta | 20 | 2026-11-12 | 2026-10-26 |
| Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) GKL-006RTU injection, Placebo - ARDS (Acute Respiratory Distress Syndrome) | Phase 1 / Phase 2 | Not yet recruiting | Beijing Gene Key Life Technology Co., Ltd | 52 | 2026-11-10 | 2026-09-30 |
| Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury in Patients With ARDS - Pilot RCT Ondansetron hydrochloride 8 mg IV Q8H, 0.9 % Normal Saline 10 ml - ARDS (Acute Respiratory Distress Syndrome), Invasive Mechanical Ventilation | Phase 2 / Phase 3 | Not yet recruiting | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 76 | 2026-10-01 | 2026-05-14 |
| High-energy Human Milk Diets in the First Two Weeks After Birth to Reduce BPD in Extremely Preterm Infants High-energy group, Standard-energy group - Extreme Prematurity, Enteral Nutrition | Phase 1 / Phase 2 | Recruiting | University of Alabama at Birmingham | 150 | 2026-09-21 | 2026-09-24 |
| Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure Simvastatin, Baricitinib - ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory Failure | Phase 2 | Not yet recruiting | University of Colorado, Denver | 300 | 2026-09-01 | 2026-10-08 |
| Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients Atibuclimab, Placebo - Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome | Phase 2 | Recruiting | Implicit Bioscience | 56 | 2026-06-17 | 2026-07-29 |
| Pressure Targeting During High Flow Therapy in Premature Infants Pressure Targeted High Flow, CPAP - Preterm Infants, Respiratory Distress Syndrome (Neonatal) | Phase 2 | Not yet recruiting | University of Texas at Austin | 78 | 2026-05-01 | 2026-02-18 |
| Lipid Infusions to Optimize Nutrition Trial SOLE, MOLE - Bronchopulmonary Dysplasia, Neurodevelopmental Impairment | Phase 2 | Recruiting | The University of Texas Health Science Center, Houston | 230 | 2026-04-29 | 2026-08-06 |
| Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below intravenous immunoglobulin - Bronchopulmonary Dysplasia | Phase 2 | Recruiting | International Peace Maternity and Child Health Hospital | 29 | 2026-04-23 | 2026-07-23 |
| Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively? Betamethasone - Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD) | Phase 2 | Not yet recruiting | Khang Nguyen | 100 | 2026-04-01 | 2026-03-03 |
| PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia montelukast 4 mg granule, Placebo - Bronchopulmonary Dysplasia (BPD), Premature Births | Phase 1 / Phase 2 | Recruiting | Duke University | 28 | 2026-02-23 | 2026-07-14 |
| A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation Placebo control group, Human-derived active intestinal bacterial liquid group - Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury(ALI) | Phase 2 / Phase 3 | Recruiting | Shanghai University of Traditional Chinese Medicine | 60 | 2025-12-10 | 2026-01-15 |
| This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction Maraviroc, Placebo - Primary Graft Dysfunction, Lung Transplantation | Phase 2 | Recruiting | University of California, San Francisco | 120 | 2025-12-07 | 2026-01-20 |
| Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients Modified Qing-Zao-Jiu-Fei Decoction (MQZJFD), Placebo - Pneumoconiosis | Phase 2 | Not yet recruiting | Chinese University of Hong Kong | 80 | 2025-11-01 | 2025-09-17 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab Cohort C: bevacizumab, Cohort C: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-10-28 | 2026-07-31 |
| Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants Human Allogenic Umbilical Cord Mesenchymal Stromal Cells, Sham procedure control - Bronchopulmonary Dysplasia (BPD), ELGAN (22-28SA) | Phase 2 | Not yet recruiting | Ottawa Hospital Research Institute | 168 | 2025-10-01 | 2025-07-10 |
| Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants Anakinra (Kineret®) - Premature Infants, Very Premature Infants | Phase 2 | Recruiting | Monash Medical Centre | 24 | 2025-06-27 | 2025-11-28 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab Cohort A: vilobelimab, Cohort A: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-06-21 | 2026-07-31 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 600 | 2025-06-10 | 2026-07-31 |
Showing 20 of 178. Sign in to see all of them.
Acute Lung Injury (77) · Bronchopulmonary Dysplasia (67) · Respiratory Distress Syndrome (58) · Premature Birth (31) · COVID-19 (19) · Radiation Pneumonitis (14) · Pneumonia (10) · Respiratory Insufficiency (9) · Sepsis (9) · Lung Neoplasms (5) · Retinopathy of Prematurity (5) · Coronavirus Infections (4) · Inflammation (4) · Lung Diseases (4)
Respiratory Tract Diseases (177) · Lung Diseases (174) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (71) · Infant, Newborn, Diseases (68) · Infant, Premature, Diseases (66) · Respiration Disorders (66) · Ventilator-Induced Lung Injury (65) · Infections (37) · Female Urogenital Diseases and Pregnancy Complications (35) · Urogenital Diseases (35) · Pregnancy Complications (34) · Pathological Conditions, Signs and Symptoms (33) · Obstetric Labor Complications (31) · Obstetric Labor, Premature (31)
Saline Solution (11) · Sodium Chloride (10) · Ascorbic Acid (6) · pirfenidone (4) · Azithromycin (3) · Budesonide (3) · calfactant (3) · nintedanib (3) · Acetylcysteine (2) · Aspirin (2) · Dexamethasone (2) · Endothelium-Dependent Relaxing Factors (2) · Furosemide (2) · Glucose (2) · Hydrocortisone (2)
NICHD Neonatal Research Network (6) · PPD Development, LP (4) · University of Alabama at Birmingham (4) · GlaxoSmithKline (3) · Medipost Co Ltd. (3) · University of North Carolina, Chapel Hill (3) · Virginia Commonwealth University (3) · APR Applied Pharma Research s.a. (2) · Affiliated Hospital to Academy of Military Medical Sciences (2) · Assistance Publique - Hôpitaux de Paris (2) · Children's Hospital of Chongqing Medical University (2) · Duke University (2) · International Peace Maternity and Child Health Hospital (2) · Mayo Clinic (2) · Monash Medical Centre (2)
United States (88) · China (25) · Canada (14) · Italy (8) · United Kingdom (8) · South Korea (7) · Spain (6) · Australia (5) · Germany (5) · Belgium (4) · Brazil (4) · France (4) · New Zealand (3) · Sweden (3) · Argentina (2)
Barbara J. Stoll, MD (4) · Seetha Shankaran, MD (4) · Waldemar A. Carlo, MD (4) · Charles R. Bauer, MD (3) · Edward F. Donovan, MD (3) · Krisa P. Van Meurs, MD (3) · Kristi L. Watterberg, MD (3) · Michele C. Walsh, MD MS (3) · Pablo J. Sanchez, MD (3) · Richard A. Ehrenkranz, MD (3) · Roger G. Faix, MD (3) · Ronald N. Goldberg, MD (3) · Abbot R. Laptook, MD (2) · Abhik Das, PhD (2)
PMID 33876883, PMID 10379020, PMID 15342835, PMID 15713907, PMID 15774846, PMID 17050868, PMID 17426195, PMID 19117865, PMID 19962042, PMID 20583979, PMID 20963840, PMID 21562125, PMID 22155140, PMID 22291116, PMID 22300564, PMID 22340260, PMID 22475409, PMID 22943074, PMID 22974830, PMID 23095978, PMID 23140612, PMID 23909719, PMID 24069180, PMID 24459776, PMID 24484547, PMID 24503265, PMID 25063725, PMID 25276362, PMID 25486575, PMID 25496504, PMID 25634565, PMID 25808113, PMID 25981908, PMID 26102252, PMID 26138630, PMID 26376074, PMID 26400297, PMID 26431718, PMID 26494395, PMID 26503312, PMID 26544934, PMID 26545141, PMID 26830686, PMID 27066464, PMID 27074126, PMID 27079965, PMID 27179988, PMID 27440140, PMID 27870826, PMID 28082531
U10HD021364 (6), U10HD021385 (5), U10HD027853 (5), U10HD027880 (5), U10HD034216 (5), U10HD021373 (4), U10HD027851 (4), U10HD027856 (4), U10HD027871 (4), U10HD036790 (4), M01RR008084 (3), U10HD021397 (3), U10HD027904 (3), U10HD040492 (3), U10HD040689 (3)